Brief: Immunicum Gets FDA Orphan Drug Designation For Ilixadencel
09/06/2022 07:05
June 9 (Reuters) - Immunicum AB IMMUN.ST :
* IMMUNICUM RECEIVED FDA ORPHAN DRUG DESIGNATION FOR
ILIXADENCEL
AS TREATMENT OF GASTROINTESTINAL STROMAL TUMORS (GIST)
Source text for Eikon: ID:nGNE79HJ7f
Further company coverage: IMMUN.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;;))